165 related articles for article (PubMed ID: 11520577)
1. Soluble recombinant HTLV-1 surface glycoprotein competitively inhibits syncytia formation and viral infection of cells.
Jassal SR; Lairmore MD; Leigh-Brown AJ; Brighty DW
Virus Res; 2001 Oct; 78(1-2):17-34. PubMed ID: 11520577
[TBL] [Abstract][Full Text] [Related]
2. Antibodies to the envelope glycoprotein of human T cell leukemia virus type 1 robustly activate cell-mediated cytotoxic responses and directly neutralize viral infectivity at multiple steps of the entry process.
Kuo CW; Mirsaliotis A; Brighty DW
J Immunol; 2011 Jul; 187(1):361-71. PubMed ID: 21646298
[TBL] [Abstract][Full Text] [Related]
3. Human T-cell leukemia virus type 1 receptor expression among syncytium-resistant cell lines revealed by a novel surface glycoprotein-immunoadhesin.
Jassal SR; Pöhler RG; Brighty DW
J Virol; 2001 Sep; 75(17):8317-28. PubMed ID: 11483777
[TBL] [Abstract][Full Text] [Related]
4. Sequence variations in the amino- and carboxy-terminal parts of the surface envelope glycoprotein of HTLV type 1 induce specific neutralizing antibodies.
Tallet B; Astier-Gin T; Moynet D; Londos-Gagliardi D; Guillemain B
AIDS Res Hum Retroviruses; 2001 Mar; 17(4):337-48. PubMed ID: 11242520
[TBL] [Abstract][Full Text] [Related]
5. Phosphatidylglycerol participates in syncytium formation induced by HTLV type 1-bearing cells.
Sagara Y; Inoue Y; Kojima E; Ishida C; Shiraki H; Maeda Y
AIDS Res Hum Retroviruses; 2001 Jan; 17(2):125-35. PubMed ID: 11177392
[TBL] [Abstract][Full Text] [Related]
6. The synthetic peptide P-197 inhibits human T-cell leukemia virus type 1 envelope-mediated syncytium formation by a mechanism that is independent of Hsc70.
Brighty DW; Jassal SR
J Virol; 2001 Nov; 75(21):10472-8. PubMed ID: 11581416
[TBL] [Abstract][Full Text] [Related]
7. A source of glycosylated human T-cell lymphotropic virus type 1 envelope protein: expression of gp46 by the vaccinia virus/T7 polymerase system.
Arp J; LeVatte M; Rowe J; Perkins S; King E; Leystra-Lantz C; Foung SK; Dekaban GA
J Virol; 1996 Nov; 70(11):7349-59. PubMed ID: 8892853
[TBL] [Abstract][Full Text] [Related]
8. Trypsin-sensitive and -resistant components in human T-cell membranes required for syncytium formation by human T-cell lymphotropic virus type 1-bearing cells.
Sagara Y; Ishida C; Inoue Y; Shiraki H; Maeda Y
J Virol; 1997 Jan; 71(1):601-7. PubMed ID: 8985389
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of cell-free human T-cell leukemia virus type 1 infection at a postbinding step by the synthetic peptide derived from an ectodomain of the gp21 transmembrane glycoprotein.
Jinno A; Haraguchi Y; Shiraki H; Hoshino H
J Virol; 1999 Nov; 73(11):9683-9. PubMed ID: 10516085
[TBL] [Abstract][Full Text] [Related]
10. Mapping of immunogenic regions of human T cell leukemia virus type I (HTLV-I) gp46 and gp21 envelope glycoproteins with env-encoded synthetic peptides and a monoclonal antibody to gp46.
Palker TJ; Tanner ME; Scearce RM; Streilein RD; Clark ME; Haynes BF
J Immunol; 1989 Feb; 142(3):971-8. PubMed ID: 2563272
[TBL] [Abstract][Full Text] [Related]
11. Human T-cell leukemia virus type 1 envelope glycoprotein gp46 interacts with cell surface heparan sulfate proteoglycans.
Piñon JD; Klasse PJ; Jassal SR; Welson S; Weber J; Brighty DW; Sattentau QJ
J Virol; 2003 Sep; 77(18):9922-30. PubMed ID: 12941902
[TBL] [Abstract][Full Text] [Related]
12. HTLV type 1 envelope glycoprotein gp46 evokes necrosis by binding to receptor complex.
Sagara Y; Inoue Y; Kojima E; Shiraki H; Maeda Y
AIDS Res Hum Retroviruses; 2000 Nov; 16(16):1701-4. PubMed ID: 11080813
[TBL] [Abstract][Full Text] [Related]
13. The humoral immune response to human T-cell lymphotropic virus type 1 envelope glycoprotein gp46 is directed primarily against conformational epitopes.
Hadlock KG; Rowe J; Foung SK
J Virol; 1999 Feb; 73(2):1205-12. PubMed ID: 9882322
[TBL] [Abstract][Full Text] [Related]
14. Structural and immunogenicity analysis of chimeric B-cell epitope constructs derived from the gp46 and gp21 subunits of the envelope glycoproteins of HTLV-1.
Sundaram R; Beebe M; Kaumaya PT
J Pept Res; 2004 Feb; 63(2):132-40. PubMed ID: 15009534
[TBL] [Abstract][Full Text] [Related]
15. Identification of novel neutralization-inducing regions of the human T cell lymphotropic virus type I envelope glycoproteins with human HTLV-I-seropositive sera.
Desgranges C; Souche S; Vernant JC; Smadja D; Vahlne A; Horal P
AIDS Res Hum Retroviruses; 1994 Feb; 10(2):163-73. PubMed ID: 8198868
[TBL] [Abstract][Full Text] [Related]
16. HTLV-1-induced cell fusion is limited at two distinct steps in the fusion pathway after receptor binding.
Daenke S; Booth S
J Cell Sci; 2000 Jan; 113 ( Pt 1)():37-44. PubMed ID: 10591623
[TBL] [Abstract][Full Text] [Related]
17. Interaction of CD82 tetraspanin proteins with HTLV-1 envelope glycoproteins inhibits cell-to-cell fusion and virus transmission.
Pique C; Lagaudrière-Gesbert C; Delamarre L; Rosenberg AR; Conjeaud H; Dokhélar MC
Virology; 2000 Oct; 276(2):455-65. PubMed ID: 11040136
[TBL] [Abstract][Full Text] [Related]
18. Molecular cloning, expression, and biological characterization of an HTLV-II envelope glycoprotein: HIV-1 expression is permissive for HTLV-II-induced cell fusion.
Wang B; Agadjanyan MG; Srikantan V; Ugen KE; Hall W; Kaplan MH; Dang K; Williams WV; Weiner DB
AIDS Res Hum Retroviruses; 1993 Sep; 9(9):849-60. PubMed ID: 8257634
[TBL] [Abstract][Full Text] [Related]
19. Sequence analysis of an immunogenic and neutralizing domain of the human T-cell lymphoma/leukemia virus type I gp46 surface membrane protein among various primate T-cell lymphoma/leukemia virus isolates including those from a patient with both HTLV-I-associated myelopathy and adult T-cell leukemia.
Sherman MP; Dube S; Spicer TP; Kane TD; Love JL; Saksena NK; Iannone R; Gibbs CJ; Yanagihara R; Dube DK
Cancer Res; 1993 Dec; 53(24):6067-73. PubMed ID: 8261424
[TBL] [Abstract][Full Text] [Related]
20. Conformation-specific antibodies targeting the trimer-of-hairpins motif of the human T-cell leukemia virus type 1 transmembrane glycoprotein recognize the viral envelope but fail to neutralize viral entry.
Mirsaliotis A; Nurkiyanova K; Lamb D; Woof JM; Brighty DW
J Virol; 2007 Jun; 81(11):6019-31. PubMed ID: 17376912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
